Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study

INTRODUCTION: Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopenia refractory to other treatments. To mitigate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Schipperus, Martin, Kaiafa, Georgia, Taylor, Louise, Wetten, Sally, Kreuzbauer, Georg, Boshier, Andy, Seesaghur, Anouchka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373377/
https://www.ncbi.nlm.nih.gov/pubmed/30232740
http://dx.doi.org/10.1007/s40264-018-0723-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373377/
https://www.ncbi.nlm.nih.gov/pubmed/30232740
http://dx.doi.org/10.1007/s40264-018-0723-6

Ejemplares similares